| 000 | 01509 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515015738.0 | ||
| 264 | 0 | _c20060524 | |
| 008 | 200605s 0 0 eng d | ||
| 022 | _a0176-3679 | ||
| 024 | 7 |
_a10.1055/s-2006-931485 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGründer, G | |
| 245 | 0 | 0 |
_aAripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. _h[electronic resource] |
| 260 |
_bPharmacopsychiatry _cFeb 2006 |
||
| 300 |
_aS21-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
| 650 | 0 | 4 | _aAripiprazole |
| 650 | 0 | 4 |
_aCerebral Cortex _xdrug effects |
| 650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
| 650 | 0 | 4 |
_aDopamine Agonists _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLimbic System _xdrug effects |
| 650 | 0 | 4 |
_aMesencephalon _xdrug effects |
| 650 | 0 | 4 |
_aNeural Pathways _xdrug effects |
| 650 | 0 | 4 |
_aPiperazines _xadverse effects |
| 650 | 0 | 4 |
_aQuinolones _xadverse effects |
| 650 | 0 | 4 |
_aReceptors, Dopamine D2 _xagonists |
| 650 | 0 | 4 |
_aSchizophrenia _xdiagnosis |
| 650 | 0 | 4 | _aSchizophrenic Psychology |
| 650 | 0 | 4 | _aSerotonin 5-HT2 Receptor Antagonists |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKungel, M | |
| 700 | 1 | _aEbrecht, M | |
| 700 | 1 | _aGöröcs, T | |
| 700 | 1 | _aModell, S | |
| 773 | 0 |
_tPharmacopsychiatry _gvol. 39 Suppl 1 _gp. S21-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1055/s-2006-931485 _zAvailable from publisher's website |
| 999 |
_c16119265 _d16119265 |
||